These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19722284)

  • 21. Anthrax Toxin Protective Antigen Variants That Selectively Utilize either the CMG2 or TEM8 Receptors for Cellular Uptake and Tumor Targeting.
    Chen KH; Liu S; Leysath CE; Miller-Randolph S; Zhang Y; Fattah R; Bugge TH; Leppla SH
    J Biol Chem; 2016 Oct; 291(42):22021-22029. PubMed ID: 27555325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A receptor-based switch that regulates anthrax toxin pore formation.
    Pilpa RM; Bayrhuber M; Marlett JM; Riek R; Young JA
    PLoS Pathog; 2011 Dec; 7(12):e1002354. PubMed ID: 22174672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anthrax protective antigen: prepore-to-pore conversion.
    Miller CJ; Elliott JL; Collier RJ
    Biochemistry; 1999 Aug; 38(32):10432-41. PubMed ID: 10441138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor.
    Scobie HM; Rainey GJ; Bradley KA; Young JA
    Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5170-4. PubMed ID: 12700348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The CMG2 ELISA for evaluating inhibitors of the binding of anthrax toxin protective antigen to its receptor.
    Dawson RM
    J Pharmacol Toxicol Methods; 2009; 59(1):50-5. PubMed ID: 19049885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The receptors that mediate the direct lethality of anthrax toxin.
    Liu S; Zhang Y; Hoover B; Leppla SH
    Toxins (Basel); 2012 Dec; 5(1):1-8. PubMed ID: 23271637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo.
    Liu S; Crown D; Miller-Randolph S; Moayeri M; Wang H; Hu H; Morley T; Leppla SH
    Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12424-9. PubMed ID: 19617532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein.
    Rogers MS; Cryan LM; Habeshian KA; Bazinet L; Caldwell TP; Ackroyd PC; Christensen KA
    PLoS One; 2012; 7(6):e39911. PubMed ID: 22768167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anthrax toxin: receptor binding, internalization, pore formation, and translocation.
    Young JA; Collier RJ
    Annu Rev Biochem; 2007; 76():243-65. PubMed ID: 17335404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A protective antigen mutation increases the pH threshold of anthrax toxin receptor 2-mediated pore formation.
    Dennis MK; Mogridge J
    Biochemistry; 2014 Apr; 53(13):2166-71. PubMed ID: 24641616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular dynamics simulations of complexes between wild-type and mutant anthrax protective antigen variants and a model anthrax toxin receptor.
    Stiles L; Nelson DJ
    J Biomol Struct Dyn; 2005 Apr; 22(5):503-19. PubMed ID: 15702923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changing the receptor specificity of anthrax toxin.
    Mechaly A; McCluskey AJ; Collier RJ
    mBio; 2012; 3(3):. PubMed ID: 22550037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Membrane translocation by anthrax toxin.
    Collier RJ
    Mol Aspects Med; 2009 Dec; 30(6):413-22. PubMed ID: 19563824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probing the pH-dependent prepore to pore transition of Bacillus anthracis protective antigen with differential oxidative protein footprinting.
    Smedley JG; Sharp JS; Kuhn JF; Tomer KB
    Biochemistry; 2008 Oct; 47(40):10694-704. PubMed ID: 18785752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin.
    Martchenko M; Jeong SY; Cohen SN
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15583-8. PubMed ID: 20713715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor.
    Lacy DB; Wigelsworth DJ; Scobie HM; Young JA; Collier RJ
    Proc Natl Acad Sci U S A; 2004 Apr; 101(17):6367-72. PubMed ID: 15079089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen.
    Leysath CE; Monzingo AF; Maynard JA; Barnett J; Georgiou G; Iverson BL; Robertus JD
    J Mol Biol; 2009 Apr; 387(3):680-93. PubMed ID: 19361425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery.
    Becker L; Verdurmen WPR; Plückthun A
    BMC Biol; 2020 Aug; 18(1):100. PubMed ID: 32792013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binding of filamentous actin to anthrax toxin receptor 1 decreases its association with protective antigen.
    Garlick KM; Batty S; Mogridge J
    Biochemistry; 2012 Feb; 51(6):1249-56. PubMed ID: 22303962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystallization and preliminary X-ray analysis of the vWA domain of human anthrax toxin receptor 1.
    Cai C; Zhao Y; Tong X; Fu S; Li Y; Wu Y; Li X; Lou Z
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 Jan; 67(Pt 1):64-7. PubMed ID: 21206026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.